CMS should not pay for higher doses of oncology drugs than necessary. In cancer treatment, higher doses often do not produce better results. On the contrary, they are accompanied by worse side effects. The article is an opinion criticizing the reimbursement of excess benefits. It does not provide specific statistics or study details. It emphasizes the need for efficient use of resources for treatment.